Journal of Medicinal Chemistry · 1999 · 54 citations · 8 references
Life SciencesBiochemistryMedicinal ChemistryEnzymologyStructural BiochemistryStructural BiologyDrug-metabolizing EnzymesEnzyme InhibitionLigand BindingProtein StructureStructure-activity Relationship AnalysisActive Site AnalysisActive SitesBuried Active SitesCrystal Structure PredictionCrystal Structure RefinementEnzymesHydrogen BondingOxidoreductase Enzymes
The crystal structure of human DT-diaphorase (NAD(P)H oxidoreductase (quinone); EC 1.6.99.2) has been determined to 2.3 A resolution. There are only minor differences in shape and volume between the active sites of the rat and human enzymes and in the hydrophobic environment in the vicinity of the substrate. The isoalloxazine ring of the bound FAD is more buried in the human structure. Molecular modeling was used to examine optimal positions for the antitumor prodrug CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) in both the human and rat enzyme active sites. This suggests that the position of CB1954 in the active site of the human enzyme is very similar to that in the rat, although there are detailed differences in the predicted patterns of hydrogen bonding between side chains and the drug. Some of the differences are a consequence of the shift in position for the FAD molecule and may contribute to the observed differences in rate of the two-electron reduction of CB1954.
8
Pnina Dauber‐Osguthorpe, Victoria A. Roberts, David J. Osguthorpe et al. · Proteins Structure Function and Bioinformatics · 1988 · 2.1K citations
Mary Jane Long, Hans J. Prochaska, Paul Talalay · Proceedings of the National Academy of Sciences · 1986 · 152 citations · Full text